698394-60-4

Basic information

• Product Name: 2-BroMo-1-(4-ethylphenyl)-2-Methylpropan-1-one
• Synonyms: 2-BroMo-1-(4-ethylphenyl)-2-Methylpropan-1-one
• CAS NO: 698394-60-4
• Molecular Formula: C₁₂H₁₅BrO
• Molecular Weight: 255.1509
• Mol File: 698394-60-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 308.3 °C at 760 mmHg
• Flash Point: 38.5 °C
• Appearance: /
• Density: 1.275 g/cm³
• CAS DataBase Reference: 2-BroMo-1-(4-ethylphenyl)-2-Methylpropan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-1-(4-ethylphenyl)-2-Methylpropan-1-one(698394-60-4)
• EPA Substance Registry System: 2-BroMo-1-(4-ethylphenyl)-2-Methylpropan-1-one(698394-60-4)

Safety Data

• Hazardous Substances Data: 698394-60-4(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-(4-ethylphenyl)-2-methylpropan-1-one is a chemical compound with the molecular formula C11H15BrO. It is a yellow liquid with a molecular weight of 251.14 g/mol. 2-Bromo-1-(4-ethylphenyl)-2-methylpropan-1-one belongs to the family of aromatic ketones and is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a reagent in organic synthesis, particularly in the preparation of complex organic molecules. The presence of a bromine atom and an aromatic ring in its structure gives the compound unique properties and reactivity, making it a valuable building block in organic chemistry.

Upstream product

• 20469-89-0 2-bromo-2-methylpropionyl chloride 
• 100-41-4 ethylbenzene 
• 20769-85-1 2-bromoisobutyric acid bromide 

Downstream Products

• 1256584-73-2 2-(4-ethyl-3-iodophenyl)-2-methylpropanoic acid 
• 1247119-83-0 2-(4-ethylphenyl)-2-methyl-propanoic acid 
• 1256580-46-7 C⁽²⁴⁸⁾H₅₄₀₂ 
• 1256584-75-4 tert-butyl 6-cyano-2-[1-(4-ethyl-3-iodo-phenyl)-1-methyl-ethyl]-1H-indole-3-carboxylate 

Relevant articles and documents

Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)

A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two alectinib analogs (36 and 37) with pomalidomide through linkers of different lengths and types. The most promising degrader 17 possessed a high ALK-binding affinity and potent antiproliferative activity in the ALK-dependent cell lines and did not exhibit obvious cytotoxicity in ALK fusion-negative cells. More importantly, the efficacy of compound 17 in a Karpas 299 xenograft mouse model was further evaluated based on its ALK-sustained degradation ability in vivo. The reduction in tumor weight in the compound 17-treated group (10 mg/kg/day, I.V.) reached 75.82%, while alectinib reduced tumor weight by 63.82% at a dose of 20 mg/kg/day (P.O.). Taken together, our findings suggest that alectinib-based PROTACs associated with the degradation of ALK may have promising beneficial effects for treating ALK-driven malignancies.

Synthesis method for alectinib hydrochloride intermediate

The invention discloses a synthesis method for an alectinib hydrochloride intermediate. The synthesis method includes the following steps: 1) with 2-bromo-2-methylpropionic acid as an initial raw material, adding thionyl chloride to perform a chlorination reaction to obtain a compound (I); 2) adding ethylbenzene to the compound (I) and adding anhydrous aluminum trichloride as a catalyst to perform a substitution reaction to obtain a compound (II); 3) dissolving the compound (II) in an organic solvent, adding HC(OMe)3 and a catalyst ZnCl2, performing heat reflux until a rearrangement reaction is completely finished to obtain a compound (III); 4) dissolving the compound (III) in an organic solvent, adding iodine and iodic acid to perform a catalytic reaction to generate a compound (IV); and 5) under alkaline condition, hydrolyzing the compound (IV) to produce the target product, alectinib hydrochloride intermediate. The synthesis method is simple in operations, has high yield and is lower in cost.